1. Home
  2. VEON vs CELC Comparison

VEON vs CELC Comparison

Compare VEON & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VEON Ltd. ADS

VEON

VEON Ltd. ADS

SELL

Current Price

$78.64

Market Cap

5.2B

ML Signal

SELL

Logo Celcuity Inc.

CELC

Celcuity Inc.

SELL

Current Price

$60.63

Market Cap

4.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
VEON
CELC
Founded
1992
2011
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.2B
4.2B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
VEON
CELC
Price
$78.64
$60.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
13
Target Price
$94.50
★ $150.85
AVG Volume (30 Days)
138.4K
★ 1.1M
Earning Date
11-06-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.82
N/A
Revenue Next Year
$9.99
$1,921.71
P/E Ratio
$6.15
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$44.00
$53.54
52 Week High
$89.00
$151.02

Technical Indicators

Market Signals
Indicator
VEON
CELC
Relative Strength Index (RSI) 51.85 38.55
Support Level $77.21 $53.54
Resistance Level $87.13 $72.76
Average True Range (ATR) 3.89 4.19
MACD -0.72 -0.00
Stochastic Oscillator 40.30 4.06

Price Performance

Historical Comparison
VEON
CELC

About VEON VEON Ltd. ADS

VEON Ltd is a United Arab Emirates-based digital operator providing connectivity and Internet services to corporations and individuals. The company offers mobile and fixed-line telecommunications services through a range of traditional and broadband mobile technologies. The company's reportable segments consist of the following five segments: Pakistan, Ukraine, Kazakhstan, Bangladesh, and Uzbekistan. It provides its services under the Beeline, Kyivstar, Banglalink, and Jazz brands. It generates the majority of its revenue from Pakistan. Its telecommunications and digital services include voice, fixed broadband, data and cloud services.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: